肾细胞癌中的微小RNA：临床意义的系统评价（综述）
MicroRNAs in renal cell carcinoma: a systematic review of clinical implications (Review).
作者信息
Li Ming, Wang Ying, Song Yongsheng, Bu Renge, Yin Bo, Fei Xiang, Guo Qizhen, Wu Bin
机构信息
Department of Urology, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, P.R. China.
Department of Nuclear Medicine, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China.
出版信息
Oncol Rep. 2015 Apr;33(4):1571-8. doi: 10.3892/or.2015.3799. Epub 2015 Feb 13.
Despite recent advances in the understanding of the biology of renal cell carcinoma (RCC), successful surgical treatment and implementation of novel‑targeted therapies, the prognosis for RCC patients remains poor. Late presentation, tumor heterogeneity and in particular the lack of molecular biomarkers for early detection, classification and the surveillance of RCC treatments are major obstacles. The increasing knowledge regarding the functional role of microRNAs (miRNAs) in pathophysiological processes may provide an important link to the identification of suitable therapeutic targets and diagnostic/prognostic biomarkers for RCC. The aim of this review was to provide new insight into the function of miRNAs in the pathogenesis of RCC and to emphasize their potential as diagnostic and prognostic markers, as well as therapeutic targets.
尽管在肾细胞癌（RCC）生物学认识、成功的外科治疗及新型靶向治疗的应用方面取得了最新进展，但RCC患者的预后仍然很差。就诊时已属晚期、肿瘤异质性，尤其是缺乏用于早期检测、分类及监测RCC治疗的分子生物标志物是主要障碍。关于微小RNA（miRNA）在病理生理过程中的功能作用的认识不断增加，可能为识别RCC合适的治疗靶点及诊断/预后生物标志物提供重要联系。本综述的目的是深入了解miRNA在RCC发病机制中的作用，并强调其作为诊断和预后标志物以及治疗靶点的潜力。
Zotero 插件